Skip to content

Home
Company
Science
Pipeline
Careers
- Current Jobs
- How to Apply
Investors
Contact

ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma; ASPEN-01

Post navigation

Previous: ALX148 Enhances the Depth and Durability of Response to Multiple AML Therapies

Next: ASPEN-01: A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Trastuzumab, Ramucirumab, and Paclitaxel in Patients with 2nd Line HER2-Positive Advanced Gastric or Gastroesophageal Cancer

Home
Company
Science
Pipeline
Careers
- Current Jobs
- How to Apply
Investors
Contact

© ALX Oncology Inc., All rights reserved.
Privacy Policy Twitter LinkedIn